Verona Pharma PLC Form 4 insider transactions
Verona Pharma plc Director Anders Ullman acquired 24,000 Ordinary Shares through the vesting of Restricted Stock Units.
Verona Pharma plc's Chief Financial Officer, Mark W. Hahn, reported the vesting of performance-based Restricted Share Units and a subsequent sale of shares to cover tax obligations, alongside a new RSU award.
Form 4: Verona Pharma CMO Kathleen Rickard Reports Equity Transactions and Performance-Based RSU Award
Verona Pharma plc's Chief Medical Officer, Kathleen A. Rickard, reported routine equity transactions including the conversion of Restricted Share Units into Ordinary Shares, a tax-related share disposition, and the award of new performance-based RSUs following the achievement of Q2 2025 metrics.
Verona Pharma plc's General Counsel, Andrew Fisher, reported the acquisition of ordinary shares and restricted share units, alongside a tax-related disposition of shares, following the vesting of performance-based awards.
Verona Pharma plc's President and CEO, David Zaccardelli, reported the vesting of previously granted Restricted Share Units, a new performance-based RSU award, and a subsequent share disposition for tax obligations.
Verona Pharma plc's General Counsel, Andrew Fisher, executed a pre-planned transaction on June 16, 2025, exercising options to acquire 80,000 ordinary shares and subsequently selling an equal number of shares.
Verona Pharma plc's General Counsel, Andrew Fisher, filed an amended Form 4 with the SEC to correct a typographical error in the reported exercise price of share options.
Verona Pharma plc's Chief Financial Officer, Mark W. Hahn, sold 400,000 ordinary shares on June 11, 2025, as part of a pre-established Rule 10b5-1 trading plan.
Verona Pharma plc's President and CEO, David Zaccardelli, has reported the sale of 400,000 ordinary shares for approximately $4.56 million, executed under a Rule 10b5-1 trading plan.
Verona Pharma plc's Chief Financial Officer, Mark W. Hahn, sold a total of 390,000 Ordinary Shares over three days in late May 2025, pursuant to a Rule 10b5-1 trading plan.
Form 4: Verona Pharma CEO David Zaccardelli Sells Over 400,000 Shares Under Pre-Arranged Trading Plan
Verona Pharma plc's President and CEO, David Zaccardelli, has reported the sale of 400,000 Ordinary Shares over three days in late May 2025, executed under a Rule 10b5-1 trading plan.
Director Vikas Sinha exercised share options and sold shares of Verona Pharma plc under a pre-arranged Rule 10b5-1 trading plan.
4/A: Verona Pharma Director Vikas Sinha Corrects Form 4 Filing, Reports Transactions in Ordinary Shares
Director Vikas Sinha amends a previous Form 4 filing to accurately reflect transactions in Verona Pharma's ordinary shares rather than American Depositary Shares (ADSs).
Form 4: Verona Pharma's General Counsel, Andrew Fisher, Executes Option and Sells Shares Under 10b5-1 Plan
Andrew Fisher, General Counsel of Verona Pharma, exercised share options and sold 80,000 ordinary shares (represented by ADSs) under a pre-arranged 10b5-1 trading plan.
Director Christina Ackermann exercised share options and sold shares of Verona Pharma (VRNA) on May 14, 2025, according to a Form 4 filing.
Kathleen A. Rickard, Chief Medical Officer of Verona Pharma plc, sold ordinary shares represented by American Depositary Shares (ADSs) on May 6, 2025, under a pre-arranged Rule 10b5-1 plan.
Kathleen Rickard, Chief Medical Officer of Verona Pharma, reports the sale of ordinary shares to cover taxes related to vested Restricted Share Units (RSUs) and the vesting of performance-based RSUs.
Chief Financial Officer Mark Hahn of Verona Pharma plc reports the sale of shares to cover taxes related to vesting Restricted Share Units (RSUs) and sales under a 10b5-1 plan.
Director David R. Ebsworth exercised stock options to acquire 140,000 ordinary shares of Verona Pharma plc at a price of $1.9338 per share on May 1, 2025.
David Zaccardelli, CEO of Verona Pharma, reports the sale of ordinary shares to cover taxes related to vesting Restricted Share Units (RSUs) and sales pursuant to a 10b5-1 plan, along with the vesting of performance-based RSUs.
Andrew Fisher, General Counsel of Verona Pharma, reports the acquisition and disposal of ordinary shares and restricted share units, including transactions to cover taxes related to vesting.
David Zaccardelli, CEO of Verona Pharma, reports the acquisition and disposal of ordinary shares, as well as awards of Restricted Share Units (RSUs).
Kathleen Rickard, Chief Medical Officer of Verona Pharma, reports the acquisition and disposal of ordinary shares related to the vesting of Restricted Share Units (RSUs), including sales to cover tax obligations.
Chief Financial Officer Mark Hahn of Verona Pharma plc reports the acquisition and disposal of ordinary shares, including sales to cover taxes related to vested Restricted Share Units (RSUs).
Director Vikas Sinha exercised share options and sold shares of Verona Pharma plc on April 29, 2025, according to a recent SEC filing.
Director David R. Ebsworth receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.
Director Anders Ullman receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.
Director Vikas Sinha received 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.
Director Mahendra Shah receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.
Director Martin Edwards receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.